During this segment of his interview, Bissonnette discussed safety data on JNJ-2113 for patients with plaque psoriasis and later went into future research topics.
Related Keywords
Robert Bissonnette , Innovaderm Research , Chief Executive Officer , Il 23 , Coral , Inhibitor , Jnj 2113 , Jnj , Bissonnette , Interview , Safety , Phase , Psoriasis ,
comparemela.com © 2020. All Rights Reserved.